197 related articles for article (PubMed ID: 31329165)
1. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.
Okimoto RA; Wu W; Nanjo S; Olivas V; Lin YK; Ponce RK; Oyama R; Kondo T; Bivona TG
J Clin Invest; 2019 Jul; 129(8):3401-3406. PubMed ID: 31329165
[TBL] [Abstract][Full Text] [Related]
2. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma.
Lin YK; Wu W; Ponce RK; Kim JW; Okimoto RA
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20776-20784. PubMed ID: 32788348
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice.
Hendrickson PG; Oristian KM; Browne MR; Luo L; Ma Y; Cardona DM; Nash JO; Ballester PL; Davidson S; Shlien A; Linardic CM; Kirsch DG
Oncogene; 2024 Apr; 43(16):1223-1230. PubMed ID: 38413794
[TBL] [Abstract][Full Text] [Related]
4. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities.
Specht K; Sung YS; Zhang L; Richter GH; Fletcher CD; Antonescu CR
Genes Chromosomes Cancer; 2014 Jul; 53(7):622-33. PubMed ID: 24723486
[TBL] [Abstract][Full Text] [Related]
5. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas.
Graham C; Chilton-MacNeill S; Zielenska M; Somers GR
Hum Pathol; 2012 Feb; 43(2):180-9. PubMed ID: 21813156
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of five cases of CIC::DUX4 positive sarcomas, including literature review.
Rekhi B; Rumdee R; Shetty O
Ann Diagn Pathol; 2023 Aug; 65():152153. PubMed ID: 37167753
[TBL] [Abstract][Full Text] [Related]
7. WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.
Ponce RKM; Thomas NJ; Bui NQ; Kondo T; Okimoto RA
JCI Insight; 2022 Mar; 7(6):. PubMed ID: 35315355
[TBL] [Abstract][Full Text] [Related]
8. Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Carrabotta M; Laginestra MA; Durante G; Mancarella C; Landuzzi L; Parra A; Ruzzi F; Toracchio L; De Feo A; Giusti V; Pasello M; Righi A; Lollini PL; Palmerini E; Donati DM; Manara MC; Scotlandi K
Cancer Res; 2022 Feb; 82(4):708-720. PubMed ID: 34903601
[TBL] [Abstract][Full Text] [Related]
9. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation.
Kawamura-Saito M; Yamazaki Y; Kaneko K; Kawaguchi N; Kanda H; Mukai H; Gotoh T; Motoi T; Fukayama M; Aburatani H; Takizawa T; Nakamura T
Hum Mol Genet; 2006 Jul; 15(13):2125-37. PubMed ID: 16717057
[TBL] [Abstract][Full Text] [Related]
10. Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases.
Antonescu CR; Owosho AA; Zhang L; Chen S; Deniz K; Huryn JM; Kao YC; Huang SC; Singer S; Tap W; Schaefer IM; Fletcher CD
Am J Surg Pathol; 2017 Jul; 41(7):941-949. PubMed ID: 28346326
[TBL] [Abstract][Full Text] [Related]
11. Undifferentiated round cell sarcomas with CIC-DUX4 gene fusion: expanding the clinical spectrum.
Brčić I; Brodowicz T; Cerroni L; Kashofer K; Serbanescu GL; Kasseroler MT; Amann G; Scheipl S; Szkandera J; Leithner A; Liegl-Atzwanger B
Pathology; 2020 Feb; 52(2):236-242. PubMed ID: 31870501
[TBL] [Abstract][Full Text] [Related]
12. A t(4;19) pediatric undifferentiated sarcoma with a novel variant of the CIC-DUX4 fusion transcript.
Krskova L; Stejskalova E; Kabickova E; Mrhalova M; Kodet R
Pathol Res Pract; 2017 Mar; 213(3):281-285. PubMed ID: 28062084
[TBL] [Abstract][Full Text] [Related]
13. DUX4 Immunohistochemistry Is a Highly Sensitive and Specific Marker for CIC-DUX4 Fusion-positive Round Cell Tumor.
Siegele B; Roberts J; Black JO; Rudzinski E; Vargas SO; Galambos C
Am J Surg Pathol; 2017 Mar; 41(3):423-429. PubMed ID: 27879517
[TBL] [Abstract][Full Text] [Related]
14. Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models.
Hendrickson PG; Oristian KM; Browne MR; Lou L; Ma Y; Cardona DM; Linardic CM; Kirsch DG
bioRxiv; 2023 Sep; ():. PubMed ID: 37808628
[TBL] [Abstract][Full Text] [Related]
15. Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models.
Hendrickson PG; Oristian KM; Browne MR; Luo L; Ma Y; Cardona DM; Linardic CM; Kirsch DG
Res Sq; 2023 Oct; ():. PubMed ID: 37961185
[TBL] [Abstract][Full Text] [Related]
16. The CAM Model for
Komatsu A; Matsumoto K; Yoshimatsu Y; Sin Y; Kubota A; Saito T; Mizumoto A; Ohashi S; Muto M; Noguchi R; Kondo T; Tamanoi F
Cells; 2021 Oct; 10(10):. PubMed ID: 34685592
[TBL] [Abstract][Full Text] [Related]
17. Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma.
Thomas NJ; Luck C; Shlimon N; Ponce RK; Kosibaty Z; Okimoto RA
bioRxiv; 2023 Oct; ():. PubMed ID: 37873100
[TBL] [Abstract][Full Text] [Related]
18. Distinct histologic and genetic characteristics of round cell sarcoma with CIC-DUX4 fusion and comparison with ewing sarcoma.
Song MJ; Cho KJ; Kim TI; Kim W; Song JS
Pathol Res Pract; 2022 Mar; 231():153779. PubMed ID: 35151033
[TBL] [Abstract][Full Text] [Related]
19. Round cell sarcoma with CIC-DUX4 gene fusion: Discussion of the distinctive cytomorphologic, immunohistochemical, and molecular features in the differential diagnosis of round cell tumors.
Chebib I; Jo VY
Cancer Cytopathol; 2016 May; 124(5):350-61. PubMed ID: 26800124
[TBL] [Abstract][Full Text] [Related]
20. ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas: a study of 127 cases including mimicking lesions.
Le Guellec S; Velasco V; Pérot G; Watson S; Tirode F; Coindre JM
Mod Pathol; 2016 Dec; 29(12):1523-1531. PubMed ID: 27562494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
